We are live on ! Find out more
TSVT

2seventy bio

Delisted

TSVT was delisted on the 13th of May, 2025.

149 hedge funds and large institutions have $505M invested in 2seventy bio in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 61 increasing their positions, 30 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

184% more call options, than puts

Call options by funds: $1.16M | Put options by funds: $407K

103% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 30

14% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 22

2% more funds holding

Funds holding: 146149 (+3)

1% less capital invested

Capital invested by funds: $508M → $505M (-$3.26M)

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
149
Holders Change
+3
Holders Change %
+2.05%
% of All Funds
2.34%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
25
Increased
61
Reduced
30
Closed
22
Calls
$1.16M
Puts
$407K
Net Calls
+$748K
Net Calls Change
+$456K
Name Holding Trade Value Shares
Change
Change in
Stake
KCM
1
Kynam Capital Management
New Jersey
$49.5M +$12.2M +1,151,734 +31%
BlackRock
2
BlackRock
New York
$41.8M +$10.3M +974,661 +31%
Vanguard Group
3
Vanguard Group
Pennsylvania
$35.2M +$6.07M +573,640 +20%
State Street
4
State Street
Massachusetts
$31M -$923K -87,183 -3%
Millennium Management
5
Millennium Management
New York
$29.3M +$10.1M +952,858 +49%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$29.1M +$1.17M +110,480 +4%
BBA
7
Baker Bros. Advisors
New York
$25.3M
O
8
OrbiMed
New York
$24.2M
CC
9
Casdin Capital
New York
$20.5M
Goldman Sachs
10
Goldman Sachs
New York
$16.4M -$1.31M -123,270 -7%
ECM
11
ExodusPoint Capital Management
New York
$14.7M +$4.54M +428,350 +42%
BCLSI
12
Bain Capital Life Sciences Investors
Massachusetts
$14.3M
APM
13
Avidity Partners Management
Texas
$13.6M +$14.2M +1,342,000 New
Point72 Asset Management
14
Point72 Asset Management
Connecticut
$12.9M +$11.3M +1,065,673 +504%
JP Morgan Chase
15
JP Morgan Chase
New York
$11.9M -$4.36M -411,467 -26%
CS
16
Credit Suisse
Switzerland
$10.3M +$31.5K +2,979 +0.3%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$9.95M +$2.56M +241,754 +33%
CA
18
CHI Advisors
New York
$8.62M -$31.7K -2,993 -0.4%
Morgan Stanley
19
Morgan Stanley
New York
$7.86M -$4.11M -388,205 -33%
NM
20
Newtyn Management
New York
$7.47M -$8.12M -767,256 -51%
CCP
21
Clough Capital Partners
Massachusetts
$5.35M +$2.97M +280,500 +113%
Jacobs Levy Equity Management
22
Jacobs Levy Equity Management
New Jersey
$5.28M +$4.29M +405,084 +349%
DCM
23
DAFNA Capital Management
California
$5.02M +$5.26M +496,416 New
SAM
24
Sectoral Asset Management
Quebec, Canada
$4.68M -$143K -13,515 -3%
BC
25
Boxer Capital
California
$4.65M

TSVT Hedge Fund Activity: Q2 2023 in Review

149 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q2 2023, worth a combined $505M — down 0.64% from $508M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new TSVT positions and 22 closed out — a net gain of 3 holders — while 61 added to existing stakes and 30 trimmed.

The largest buyer was Avidity Partners Management, opening a new position worth an estimated $14.2M. The largest seller was Citadel Advisors, cutting an estimated $22.9M.

  • 149 institutional investors held 2seventy bio (TSVT) as of Q2 2023, up from 146 in Q1 2023.
  • Funds reported $505M of 2seventy bio stock for Q2 2023, down 0.64% quarter-over-quarter.
  • 25 funds opened new 2seventy bio positions in Q2 2023 and 22 closed out, a net change of +3 holders.
  • The largest 2seventy bio buyer in Q2 2023 was Avidity Partners Management, an estimated $14.2M added.
  • The largest 2seventy bio seller in Q2 2023 was Citadel Advisors, an estimated $22.9M sold.

Based on aggregated 13F filings for Q2 2023.